NO20041411L - 2-amino-6-(2,4,5 -substituerte-fenyl)-pyridiner for anvendelse som nitrogenoksyd syntase inhibitorer - Google Patents

2-amino-6-(2,4,5 -substituerte-fenyl)-pyridiner for anvendelse som nitrogenoksyd syntase inhibitorer

Info

Publication number
NO20041411L
NO20041411L NO20041411A NO20041411A NO20041411L NO 20041411 L NO20041411 L NO 20041411L NO 20041411 A NO20041411 A NO 20041411A NO 20041411 A NO20041411 A NO 20041411A NO 20041411 L NO20041411 L NO 20041411L
Authority
NO
Norway
Prior art keywords
phenyl
pyridin
methoxy
ethyl
nitric oxide
Prior art date
Application number
NO20041411A
Other languages
English (en)
Norwegian (no)
Inventor
Iii John Adams Lowe
Robert Alfred Volkmann
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20041411L publication Critical patent/NO20041411L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
NO20041411A 2001-10-10 2004-04-02 2-amino-6-(2,4,5 -substituerte-fenyl)-pyridiner for anvendelse som nitrogenoksyd syntase inhibitorer NO20041411L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32825301P 2001-10-10 2001-10-10
PCT/IB2002/003939 WO2003030993A1 (en) 2001-10-10 2002-09-24 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors

Publications (1)

Publication Number Publication Date
NO20041411L true NO20041411L (no) 2004-04-02

Family

ID=23280189

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041411A NO20041411L (no) 2001-10-10 2004-04-02 2-amino-6-(2,4,5 -substituerte-fenyl)-pyridiner for anvendelse som nitrogenoksyd syntase inhibitorer

Country Status (37)

Country Link
EP (1) EP1434624B1 (pl)
JP (1) JP2005506337A (pl)
KR (1) KR20040053157A (pl)
CN (1) CN1568207A (pl)
AP (1) AP2004003003A0 (pl)
AR (1) AR036763A1 (pl)
AT (1) ATE344089T1 (pl)
BG (1) BG108669A (pl)
BR (1) BR0213193A (pl)
CA (1) CA2463364A1 (pl)
CZ (1) CZ2004450A3 (pl)
DE (1) DE60215837T2 (pl)
DO (1) DOP2002000467A (pl)
EA (1) EA007074B1 (pl)
EC (1) ECSP045055A (pl)
EE (1) EE200400085A (pl)
ES (1) ES2275917T3 (pl)
GT (1) GT200200206A (pl)
HN (1) HN2002000289A (pl)
HR (1) HRP20040260A2 (pl)
HU (1) HUP0401678A3 (pl)
IL (1) IL161089A0 (pl)
IS (1) IS7171A (pl)
MA (1) MA27074A1 (pl)
MX (1) MXPA04002313A (pl)
NO (1) NO20041411L (pl)
NZ (1) NZ531591A (pl)
OA (1) OA12664A (pl)
PA (1) PA8556101A1 (pl)
PE (1) PE20030478A1 (pl)
PL (1) PL369454A1 (pl)
PY (1) PY0223361A (pl)
SK (1) SK1642004A3 (pl)
TN (1) TNSN04057A1 (pl)
UY (1) UY27476A1 (pl)
WO (1) WO2003030993A1 (pl)
ZA (1) ZA200401747B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232739A1 (en) * 2001-08-15 2003-12-18 Pfizer Inc. Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
US20080070952A1 (en) * 2005-02-21 2008-03-20 Proximagen Ltd., Inhibition or Treatment of Dyskinesia
US9540361B2 (en) * 2010-12-24 2017-01-10 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
RU2637503C1 (ru) * 2016-12-30 2017-12-05 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский государственный университет" (ТГУ, НИ ТГУ) Способ получения n2-метилдезоксигуанозина

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA49006C2 (uk) * 1996-03-29 2002-09-16 Файзер Інк. Похідні 6-фенілпіридил-2-аміну, фармацевтична композиція, спосіб інгібування синтази оксиду нітрогену у ссавців та спосіб лікування
WO1998034919A1 (en) * 1997-02-10 1998-08-13 Pfizer Products Inc. 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
PL358538A1 (pl) * 1999-05-21 2004-08-09 Pfizer Products Inc. Nowe środki farmaceutyczne dla inbibitorów NOS

Also Published As

Publication number Publication date
PY0223361A (es) 2004-04-01
OA12664A (en) 2006-06-19
SK1642004A3 (sk) 2005-04-01
DE60215837D1 (de) 2006-12-14
KR20040053157A (ko) 2004-06-23
PL369454A1 (pl) 2005-04-18
MA27074A1 (fr) 2004-12-20
HUP0401678A3 (en) 2007-05-02
HUP0401678A2 (hu) 2004-12-28
PE20030478A1 (es) 2003-06-06
ECSP045055A (es) 2004-05-28
EA200400321A1 (ru) 2004-08-26
UY27476A1 (es) 2003-05-30
DOP2002000467A (es) 2003-04-15
AR036763A1 (es) 2004-09-29
CA2463364A1 (en) 2003-04-17
BG108669A (bg) 2005-03-31
HRP20040260A2 (en) 2004-12-31
BR0213193A (pt) 2004-08-31
MXPA04002313A (es) 2005-04-08
ES2275917T3 (es) 2007-06-16
CN1568207A (zh) 2005-01-19
DE60215837T2 (de) 2007-05-16
EP1434624A1 (en) 2004-07-07
CZ2004450A3 (cs) 2005-03-16
PA8556101A1 (es) 2003-07-28
EP1434624B1 (en) 2006-11-02
JP2005506337A (ja) 2005-03-03
AP2004003003A0 (en) 2004-03-31
IS7171A (is) 2004-03-04
NZ531591A (en) 2006-04-28
ZA200401747B (en) 2005-03-03
HN2002000289A (es) 2002-12-03
GT200200206A (es) 2003-05-23
EA007074B1 (ru) 2006-06-30
WO2003030993A1 (en) 2003-04-17
IL161089A0 (en) 2004-08-31
TNSN04057A1 (fr) 2006-06-01
ATE344089T1 (de) 2006-11-15
EE200400085A (et) 2004-08-16

Similar Documents

Publication Publication Date Title
NO20072918L (no) Heteroaromatiske quinolinforbindelser, og anvendelse av disse som inhibitorer av PDE10
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
NO20065948L (no) Quinazolin-4-yl-piperidin- and cinnolin-4-yl-piperidin-derivatives som PDE10-inhibitorer for behandling av CNS forstyrrelser
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
MY143466A (en) Inhibitors of tyrosine kinases
WO2003087088A3 (en) (condensed) pyrimidone and (condensed) pyridone compounds, processes for their preparation, and pharmaceutical compositions containing them
CA2493633A1 (en) Kinase inhibitors
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
ES2195785A1 (es) Nuevos derivados de piridazin-3(2h)-ona.
TR199901917T2 (xx) 2-Amino-6-(2-ikame edilmi�-4-fenoksi)-ikame edilmi� piridinler
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
NO20054359L (no) Cykliske protein tyrosin kinase inhibitorer
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
AU3113902A (en) Thiazolyl inhibitors of tec family tyrosine kinases
DE60205776D1 (en) Indolinon-derivative als protein-kinasehemmer
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.
DE60220771D1 (de) Hemmer von cyclinabhängigen kinasen als mittel gegen krebs
WO2003006670A3 (en) 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
WO2004092144A3 (en) Quinazoline compounds useful as p38 kinase inhibitors
WO2002014281A8 (en) Pyridine derivatives as inhibitors of p38
BR0213994A (pt) Derivados heterocìclicos de glicinamida e seus usos médicos
IL179883A0 (en) 4,6-disubstituted pyrimidine derivatives and pharmaceutical compositions containing the same
SE0302756D0 (sv) Novel Compounds
MXPA05010975A (es) Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide.